[18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial
M de Wit, W Brenner, M Hartmann, J Kotzerke, D Hellwig, J Lehmann, C Franzius, S Kliesch, M Schlemmer, K Tatsch, R Heicappell, L Geworski, H Amthauer, B M Dohmen, H Schirrmeister, U Cremerius, C Bokemeyer, R Bares, M de Wit, W Brenner, M Hartmann, J Kotzerke, D Hellwig, J Lehmann, C Franzius, S Kliesch, M Schlemmer, K Tatsch, R Heicappell, L Geworski, H Amthauer, B M Dohmen, H Schirrmeister, U Cremerius, C Bokemeyer, R Bares
Abstract
Purpose: The aim of this study was to determine the predictive values of 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) in primary staging in patients with newly diagnosed non-seminomatous germ cell tumour (NSGCT) clinical stage I/II.
Patients and methods: The hypothesis was that FDG-PET would improve the negative predictive value (NPV) from 70% to 90%, thus requiring a total of 169 patients. All scans underwent visual analysis by a reference team of nuclear medicine physicians. Results were validated by histology following retroperitoneal lymph node dissection.
Results: Only 72 of the planned 169 patients were included, due to poor accrual. The prevalence of nodal involvement was 26%. Correct nodal staging by FDG-PET was achieved in 83% compared with correct computed tomography (CT) staging in 71%. CT had a sensitivity and specificity of 41% and 95%, respectively. Positive predictive value (PPV) and NPV were 87% and 67%, respectively. FDG-PET had a sensitivity and specificity of 66% and 98%, respectively. PPV was 95%. The primary end point was not reached, with an NPV of 78%.
Conclusion: FDG-PET as a primary staging tool for NSGCT yielded only slightly better results than CT. Both methods had a high specificity while false-negative findings were more frequent with CT. FDG-PET is mostly useful as a diagnostic tool in case of questionable CT scan.
Source: PubMed